SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nemeth Norbert)
 

Sökning: WFRF:(Nemeth Norbert) > Interleukin-6 as a ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003783naa a2200493 4500
001oai:lup.lub.lu.se:dea1154f-9549-4848-b101-8728b1edebae
003SwePub
008160401s2011 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/21835612 URI
0247 a https://doi.org/10.1158/1078-0432.CCR-11-09452 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Coward, Jermaine4 aut
2451 0a Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
264 1c 2011
520 a Purpose: We investigated whether inhibition of interleukin 6 (IL-6) has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network. Experimental Design: We combined preclinical and in silico experiments with a phase 2 clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer. Results: Automated immunohistochemistry on tissue microarrays from 221 ovarian cancer cases showed that intensity of IL-6 staining in malignant cells significantly associated with poor prognosis. Treatment of ovarian cancer cells with siltuximab reduced constitutive cytokine and chemokine production and also inhibited IL-6 signaling, tumor growth, the tumor-associated macrophage infiltrate and angiogenesis in IL-6-producing intraperitoneal ovarian cancer xenografts. In the clinical trial, the primary endpoint was response rate as assessed by combined RECIST and CA125 criteria. One patient of eighteen evaluable had a partial response, while seven others had periods of disease stabilization. In patients treated for 6 months, there was a significant decline in plasma levels of IL-6-regulated CCL2, CXCL12, and VEGF. Gene expression levels of factors that were reduced by siltuximab treatment in the patients significantly correlated with high IL-6 pathway gene expression and macrophage markers in microarray analyses of ovarian cancer biopsies. Conclusion: IL-6 stimulates inflammatory cytokine production, tumor angiogenesis, and the tumor macrophage infiltrate in ovarian cancer and these actions can be inhibited by a neutralizing anti-IL-6 antibody in preclinical and clinical studies. Clin Cancer Res; 17(18); 6083-96. (C) 2011 AACR.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Kulbe, Hagen4 aut
7001 a Chakravarty, Probir4 aut
7001 a Leader, David4 aut
7001 a Vassileva, Vessela4 aut
7001 a Leinster, D. Andrew4 aut
7001 a Thompson, Richard4 aut
7001 a Schioppa, Tiziana4 aut
7001 a Nemeth, Jeffery4 aut
7001 a Vermeulen, Jessica4 aut
7001 a Singh, Naveena4 aut
7001 a Avril, Norbert4 aut
7001 a Cummings, Jeff4 aut
7001 a Rexhepaj, Elton4 aut
7001 a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji
7001 a Gallagher, William M.4 aut
7001 a Brennan, Donal J.4 aut
7001 a McNeish, Iain A.4 aut
7001 a Balkwill, Frances R.4 aut
7102 a Tumörmikromiljöb Sektion I4 org
7730 t Clinical Cancer Researchg 17:18, s. 6083-6096q 17:18<6083-6096x 1078-0432
8564 u http://dx.doi.org/10.1158/1078-0432.CCR-11-0945y FULLTEXT
8564 8u https://lup.lub.lu.se/record/2183561
8564 8u https://doi.org/10.1158/1078-0432.CCR-11-0945

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy